Ase S. Lexberg

Drammen, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial.

Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: July 15, 2024

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.

Journal: The Lancet. Rheumatology

Published: October 23, 2023

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.

Journal: Annals of the rheumatic diseases

Published: May 25, 2023

Physician participation in quality improvement work- interest and opportunity: a cross-sectional survey.

Physician participation in quality improvement work- interest and opportunity: a cross-sectional survey.

Journal: BMC primary care

Published: February 09, 2022

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.

Journal: JAMA

Published: May 04, 2021

Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register.

Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register.

Journal: Drugs & aging

Published: July 11, 2020

Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project.

Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project.

Journal: RMD open

Published: May 30, 2018

Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study.

Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study.

Journal: Seminars in arthritis and rheumatism

Published: April 18, 2018

Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases.

Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases.

Journal: International journal of cardiology

Published: February 18, 2018

Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases.

Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases.

Journal: International journal of cardiology

Published: July 31, 2017

Low level of Rituximab in human breast milk in a patient treated during lactation.

Low level of Rituximab in human breast milk in a patient treated during lactation.

Journal: Rheumatology (Oxford, England)

Published: March 25, 2017

Cardiovascular disease risk profiles in inflammatory joint disease entities.

Cardiovascular disease risk profiles in inflammatory joint disease entities.

Journal: Arthritis research & therapy

Published: March 17, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026